4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- 4basebio and Genezen expanded their non-exclusive collaboration to supply enzymatically produced hpDNA® across Research Use Only, High-Quality, and GMP-grade programs for viral vector applications.
- 4basebio's cell-free synthetic DNA demonstrated ~30% lower DNA mass and transfection reagent requirements versus plasmid DNA in AAV production while maintaining comparable titers and shortening production timelines.
Operational Impact
Genezen's expanded access to 4basebio's GMP-grade hpDNA® and cell-free manufacturing process reduces material costs and production timelines for AAV-based programs, potentially improving unit economics and cycle time for viral vector CDMO customers moving into late-stage development.
Source: PharmaSource RSS
Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Artis BioSolutions launched an integrated Genetic Medicines Center of Excellence in Bilbao, Spain, offering synthetic DNA, mRNA drug substance, LNP formulation, and GMP drug-product manufacturing under one roof.
- The facility consolidates early development through commercialization services, aiming to reduce technology transfer complexity and accelerate program timelines for genetic medicine partners.
Operational Impact
Artis's Bilbao facility adds European mRNA and LNP manufacturing capacity, complementing its U.S. Boston site and enabling genetic-medicine sponsors to consolidate development and GMP manufacturing with a single CDMO partner.
Source: Contract Pharma Breaking News RSS
Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership
- Gland Pharma will build a dedicated sterile API manufacturing suite at its JNPC Visakhapatnam facility exclusively for Neuland, adding ~1,400 kg annual capacity.
- The partnership combines Neuland's complex API expertise with Gland's aseptic manufacturing capabilities, enabling integrated development-to-commercial supply for customers.
- New suite will operate to cGMP, USFDA, and EU standards, supporting multiple sterile products and future growth.
Operational Impact
Gland Pharma's new dedicated sterile API suite at Visakhapatnam increases regional CDMO capacity for complex sterile APIs, enabling Neuland to meet growing customer demand while maintaining cGMP and FDA/EU compliance standards.
Source: Contract Pharma Breaking News RSS
References
- PharmaSource RSS — 4basebio Expands Genezen Partnership for GMP Synthetic DNA in Viral Vector Manufacturing
- Contract Pharma Breaking News RSS — Artis BioSolutions Opens Genetic Medicines Center of Excellence in Bilbao
- Contract Pharma Breaking News RSS — Neuland, Gland Pharma Expand Sterile API Capacity via Visakhapatnam Partnership